Potassium-Competitive Acid Blocker
K-CAB®

Generic Name

tegoprazan

Indication

Gastroesophageal, Reflux Disease, etc.

Seller

HK inno.N Corporation (Korea)

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. (China), etc.

Product

K-CAB® (Korea), 泰欣赞® (China), etc.

Tegoprazan is a potassium-competitive acid blocker (P-CAB), a new type of gastric acid secretion inhibitor discovered by RaQualia. Proton pump inhibitors (PPIs) have been used from long ago for gastroesophageal reflux disease, however, P-CAB as a new generation of drugs suppresses gastric acid secretion more rapidly and more persistently than PPIs.

 

There are many diseases caused by excessive gastric acid secretion, and in recent years the number of patients with gastroesophageal reflux disease also known as reflux esophagitis has been particularly increasing. The global market for peptic ulcer drugs, mainly gastric acid secretion inhibitors, is valued at approximately 2 trillion yen, highlighting its substantial presence in the pharmaceutical market.

 

Tegoprazan has been developed by RaQualia’s licensee HK inno.N and its sublicensees around the world, and was launched in South Korea in 2019 as K-CAB®. The product is being delivered to patients around the world as the first human medicine from RaQualia.